The Burden of Chemotherapy-Induced Myelosuppression in Patients with Small Cell Lung Cancer: What’s New?

Sponsored webinar that reframed the landscape of Chemotherapy-induced myelosuppression (CIM) with a fresh perspective on the root of the clinical problem, the patient burden revealed through real world management of CIM, and the hope for a future that fulfills the unmet need – one made more complicated by the confounding influence of Covid-19 in the day-to-day management of people facing malignancy.
Payment Systems, Rare Diseases, Managed Care Practice Issues
Finger scanning Logo

Precision Medicine Initiative

Despite clinical guidelines, biomarker testing is unevenly applied, leaving patients without access to targeted therapies. AMCP is engaging payers and providers to align coverage with best practices, expand real-world evidence, and reduce gaps in precision medicine adoption.
Precision Medicine